Discovery & Optimization

Polpharma Biologics early stage antibody discovery and humanization platforms are designed to get you a high affinity antibody with the desired binding properties and functional activity that is ready for the next stage of your project. We can also create transient and stable cell lines to provide adequate material for early stage studies.

Monoclonal Antibody Generation

  • Generation of antibodies in rodents using the CASH™ platform (Custom Assays for Specific Hybridomas)
  • Hybridoma selection using custom developed bioassays
  • cDNA sequence (DNA) coding for VH and VL and subsequently expressed on human IgG constant region

Antibody Humanization

  • Design best-in-class humanized antibodies
  • More than 200 mAbs have been humanized using this technology. Fifteen out of the ~40 FDA-approved mAbs have been humanized using this method.
  • In silico analysis and sequences are available in 1 month. Wet work takes 4-5 months
  • Sequences immunogenicity and manufacturability assessed
  • No royalties of licence fees

Bioassay Toolbox

  • Flow Cytometry
  • Functional proprietary cell-based assays, including proprietary membrane FcγR- and FcRn-based binding assays
  • ADCC (using a proprietary effector cell line) and CDC
  • Immunogenicity and Cytokine release assays
  • Potency assays

Working with us

We are very happy to work with you on either a standalone project or as part of an integrated project to accelerate you therapeutic to patients. Either way we treat every project equally and are dedicated to delivering results and getting your therapeutic to patients.


Cell Line Development

Polpharma Biologics have over 25 years of success in generating high-yield production cell lines for innovative proteins.


Process Development

Polpharma Biologics provides full process development support, from early development of mAbs to process and analytical methods development.


Analytical Development

We can establish and qualify all required physico-chemical and bioanalytical methods in-house to fully characterize relevant target protein quality attributes.



Our drug substance process development and manufacturing services are fully integrated across our site network for seamless process transfer, scale-up and end-to-end supply chain efficiency.